CoAching CD8<sup>+</sup> T cells for tumor immunotherapy-the pantothenate way.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 34879235.
- Also identified by DOI 10.1016/j.cmet.2021.11.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The metabolic state of T cells strongly influences their effector function and anti-tumor efficacy. St. Paul et al. (2021) report that Tc22, a CD8+ T cell subset with potent anti-tumor activity, upregulates the pantothenate/coenzyme A (CoA) pathway and that treatment with CoA or pantothenate is sufficient to enhance tumor immunotherapy.
Medical subject headings
- CD8-Positive T-Lymphocytes
- Mentoring